- Global Pharma News & Resources

miRNA Sequencing and Assay Market is projected to accelerate at a CAGR of 12.5% from 2023 to 2032 | insightSLICE

The global miRNA Sequencing and Assay market size was estimated to be US$ 345 million in 2021 and is expected grow at a CAGR of 12.5% between 2023 to 2032.

The Global miRNA Sequencing and Assay Market study thoroughly examines the market, industry, and significant players. Both the supply-side and demand-side of the market have been examined in the research.

The study on the global miRNA sequencing and assay market also offers market trends by product, investment, and competitive landscape.

Proceed to purchase:

Market Overview

Small ribonucleic acids called miRNAs have a length of 21–25 nucleotides. And by inhibiting translation and degrading transcripts, this regulates protein expression. Currently, miRNA plays a key role in controlling a variety of biological processes and developmental processes, including lipid metabolism, brain development, and hematopoiesis.

Sequence independence, coverage, and other advantages of miRNA are mixed with drawbacks, including high cost, infrastructure needs, run length, and possible artefacts.

The next-generation sequencing method is used for RNA sequences like the miRNA. MiRNA is distinct from the RNA sequence and is crucial in conditions like cancer. In the coming years, nucleotide sequencing technology advancements are anticipated to drive market expansion.

MiRNA is a crucial biomarker in many disorders, including cancer, as its dysregulation leads to tumour growth and malignancy. Additionally, boosting the use of miRNA is likely to enhance market investment.

Additionally, the market’s expansion is primarily fueled by benefits offered by miRNA sequencing over other technologies, increased research funding for genomics, and the decreasing cost of sequencing.

The key players of the Global miRNA Sequencing and Assay Market are:

Illumina, Inc. and Thermo Fisher Scientific, Inc. are the key market players. These businesses’ growing product and service portfolios have enhanced income generation from miRNA sequencing and assays. Additionally, the companies’ strong distribution networks have considerably sped up expansion. QIAGEN, Oxford Nanopore Technologies, Takara Bio, Perkinelmer Inc., Trilink Biotechnologies, Lexogen GmbH, Norgen Biotek Corp., and Maravai LifeSciences are additional vital players.

Access the sample report:

Driving factors for the growth of Global miRNA Sequencing and Assay Market

Next-generation sequencing is often preferred over microarrays for miRNA sequence analysis because it provides a superior signal-to-noise ratio and makes sequencing more effective.

Besides, short RNAs like siRNA, piRNA, and miRNA participate in RNA-mediated epigenetic control of cellular functions like gene expression and cell death, as well as the differentiation and development of cells.

Short RNA sequence analysis facilitates the discovery of novel miRNAs and other small RNAs and helps to assess whether these nucleic acids are differentially expressed in different samples.

The process can be used to analyze miRNAs without knowing their secondary structure or sequence and to identify variations like isomiRs at the single-base resolution.

Likewise, the growing use of analytic sequencing techniques has driven large expenditures by key industry players. As a result, a significant product line has quickly expanded on the market.

Most of these products are upgrades to biotechnology products already available on the market. As a result, existing players in the market can now launch and develop products more quickly than newcomers.

Growth in the prevalence of infectious and communicable diseases is anticipated, and developments made possible by cutting-edge technology and the use of novel approaches to access the sequence of miRNA are anticipated to drive market growth.

Surging cancer incidence rates, growing acceptance of conceivable sequencing techniques, and developments in genetic research are all predicted to support market expansion shortly.

An upgrade in interest in miRNA biomarker discoveries may support the sequencing and assay markets for miRNA growth. In addition, factors like the increased prevalence of neurological diseases and the increased demand for customized medications are to blame for the market’s growth.

Global miRNA Sequencing and Assay Market Key Segments:

By Product & Service

  • Products
    • Library Preparation Kits
    • Sequencing Consumables
    • Instruments
  • Services

By Technology

  • Sequencing (Seq.) By Synthesis
  • By Oligonucleotide Ligation and Detection (SOLiD)
  • Nanopore Seq.
  • Sanger Seq.
  • Single Molecule Real-time (SMRT) Seq.

By Workflow

  • Library Preparation
  • Sequencing
  • Data Analysis & Storage
  • By Application Outlook
  • Cancer
  • Polyglutamine Diseases
  • Autoimmune Disease
  • Schizophrenia
  • Others

By End-use

  • Pharmaceutical & Biotechnology Industry
  • Research and Academic Institutes
  • Contract Research Organizations

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • the United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

The leading market segments of Global miRNA Sequencing and Assay Market

With majority revenue share, the cancer segment dominated the miRNA sequencing and test market. MiRNAs that are dysregulated are thought to belong to a new class of tumour suppressor genes. During the projected period, the application sector for polyglutamine disorders is anticipated to have the highest CAGR.

With a majority revenue share, the sequencing by Synthesis (SBS) technology segment dominated the market. With more than 50% revenue share, the sequencing workflow sector continued to hold the lead in the miRNA sequencing and assay market.

The product division held the largest revenue share of the market, higher than 75%. Several academic institutions are receiving bids to expedite the miRNA sequencing and assay research. It is anticipated that the pharmaceutical and biotechnology industry sector will experience a sizable CAGR during the forecast period.

Related reports:

Global Parenteral Nutrition Market:

Global Geriatric Medicines Market:

Regional performance of miRNA Sequencing and Assay Market

North America dominated the market in 2021 with a revenue share of over 42.0% because of significant businesses like PerkinElmer, Inc. and Thermo Fisher Scientific, which have increased their R&D for developing diseases. Businesses in this region are creating new goods to expand their product lines.

For instance, to advance its current technology and produce new sequence analysis technology in 2020, Illumina, Inc. spent USD 682 million on research and development. These factors are further fostering regional growth.

Asia Pacific is likely to witness the quickest growth during the forecast timeframe due to vast number of associations and organizations striving to educate young scientists in this region.

One such network is APBioNet, which not only exchanges data and information but also organizes conferences, workshops, and training sessions in addition to monitoring the development of the bioinformatics infrastructure.

Read more about the report inclusions:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 06-Dec-2022